The Associations of Antihypertensive Medications, Steroids, Beta Blockers, Statins and Comorbidities with COVID-19 Outcomes in Patients with and without Chronic Kidney Disease: A Retrospective Study

(1) Background: Data on COVID-19 outcomes and disease course as a function of different medications used to treat cardiovascular chronic kidney (CKD), well the presence comorbidities in primarily Black cohorts, are lacking. (2) Methods: We conducted retrospective medical chart review 327 patients (62.6% race) who were admitted Detroit Medical Center, Detroit, MI. Group differences (CKD vs. non-CKD) compared using Pearson χ2 test. univariate multivariate regression analyses for factors contributing death during hospitalization due (primary outcome) ICU admission (secondary outcome), adjusting age, sex, medications, comorbidities. A sub-analysis was also completed CKD patients. (3) Results: In fully adjusted model, protective effect ACEi alone, but not combination with ARB or CCB, found (OR = 0.400, 95% CI [0.183–0.874]). Heart failure significantly associated primary outcome 4.088, [1.1661–14.387]), COPD 3.747, [1.591–8.828]). (4) Conclusions: Therapeutic strategies milieu may need be tailored more prudently individuals COVID-19, especially individuals.